Epigenetic-based companion diagnostics

Personalized Medicine
Leander Van NesteJames S Clark

Abstract

In current medical practice, when a patient is diagnosed with cancer the treating physician generally follows a standard protocol, assigning the treatment that gives a favorable response in the largest proportion of patients. However, in many individual instances this approach may not be the most effective solution and, typically, treatment is only initiated or altered once the cancer has actually started progressing. During this process, patients will lose treatment time waiting to start chemotherapy or will endure severe side effects associated with toxic chemotherapeutic treatments. While some patients are undertreated because current diagnostic methods cannot provide accurate enough information regarding the aggressiveness or drug response of their disease, others with nonaggressive forms of cancer are overtreated and unnecessarily undergo the side effects associated with chemotherapeutic treatment. Epigenetic markers have been widely investigated and are considered key regulators of cellular transcription. Histone modifications and DNA methylation have been demonstrated to play key roles in maintaining stem-cell-like states, cellular differentiation and cancer. In particular, DNA methylation is a frequent, abundant and sta...Continue Reading

References

Jul 20, 1987·Journal of Molecular Biology·M Gardiner-Garden, M Frommer
May 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S F WolfB R Migeon
Apr 1, 1995·Nature Genetics·K D TremblayM S Bartolomei
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·M L VeiglS D Markowitz
Sep 29, 1999·Genes & Development·X ZhangM O Robinson
Jul 25, 2000·Trends in Genetics : TIG·J Ahringer
Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
Jan 11, 2000·Nucleic Acids Research·C GrunauG Roizes
Apr 28, 2001·Trends in Molecular Medicine·B B SpearJ Huff
Oct 2, 2001·Cancer Control : Journal of the Moffitt Cancer Center·N M Diaz
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Apr 2, 2004·Nature Reviews. Cancer·Stanton L Gerson
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Mar 31, 2005·Current Opinion in Genetics & Development·Raphael MargueronDanny Reinberg
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven A BelinskyMaria A Picchi
Oct 15, 2005·Nucleic Acids Research·Alexander MeissnerRudolf Jaenisch
Feb 2, 2006·Genome Research·Marina BibikovaJian-Bing Fan
Nov 30, 2006·Journal of Cellular Physiology·M R MatarazzoM D'Esposito
Jan 30, 2007·Nucleic Acids Research·Mathias EhrichDirk van den Boom
Sep 26, 2007·PLoS Genetics·Kornel E SchuebelStephen B Baylin
Feb 8, 2008·BioTechniques·Filipe V JacintoManel Esteller
Feb 23, 2008·Nature Reviews. Molecular Cell Biology·Xiang-Jiao Yang, Edward Seto
Mar 11, 2008·Epigenetics : Official Journal of the DNA Methylation Society·John M Mariadason
Mar 14, 2008·The New England Journal of Medicine·Malcolm V BrockJames G Herman
Jul 5, 2008·Nature·Alexander MeissnerEric S Lander
Feb 27, 2009·Clinical Pharmacology and Therapeutics·A Gomez, M Ingelman-Sundberg
Mar 31, 2009·Nature Biotechnology·Madeleine P BallGeorge M Church
Jul 28, 2009·Clinical Colorectal Cancer·Tanios Bekaii-Saab
May 7, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ahmad JowaedUllrich Wüllner

❮ Previous
Next ❯

Citations

Sep 11, 2014·Cellular Oncology (Dordrecht)·Leander Van Neste, Wim Van Criekinge

❮ Previous
Next ❯

Methods Mentioned

BETA
immunoprecipitation
acetylation
methylation profiling
MBD-seq
immunoprecipitation-seq
PCR

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.